Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

ClinicalTrials.gov ID: NCT00325442

Public ClinicalTrials.gov record NCT00325442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits occurred at 4 week intervals for 16 weeks; the key measure of efficacy was the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. One optional substudy was also a part of FREEDOM-C at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 16. Patients who completed all assessments for 16-weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).

Study identification

NCT ID
NCT00325442
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
United Therapeutics
Industry
Enrollment
354 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2006
Primary completion
Aug 31, 2008
Completion
Nov 30, 2010
Last update posted
Aug 1, 2017

2006 – 2010

United States locations

U.S. sites
39
U.S. states
24
U.S. cities
34
Facility City State ZIP Site status
University of Alabama-Birmingham Birmingham Alabama 35294
Arizona Pulmonary Specialist Phoenix Arizona 85013
University of Arizona Health Science Center Tucson Arizona 85724
West Los Angeles VA Healthcare Center Los Angeles California 90073
Stanford University, Pulmonary and Critical Care Palo Alto California 94305
UC Davis Medical Center Sacramento California 95817
University of California-San Francisco San Francisco California 94143
Harbour-UCLA Medical Center Torrance California 90502
The Children's Hospital Aurora Colorado 80218
Pulmonary Hypertension Clinic Aurora Colorado 80262
University of Chicago Chicago Illinois 60637
University of Iowa Health Care Iowa City Iowa 52242
Maine Medical Center Portland Maine 04102
University of Maryland School of Medicine Baltimore Maryland 21201
John's Hopkins Hospital Baltimore Maryland 21205
Tufts Medical Center Boston Massachusetts 02111
Massachusetts General Hospital Boston Massachusetts 02114
University of Michigan Ann Arbor Michigan 48109
University of Minnesota Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Washington University Hospital St Louis Missouri 63110
Columbia Presbyterian Medical Center New York New York 10032
Mary M Parkes Center for Asthma, Allergy and Pulmonary Care Rochester New York 14643
Duke University Medical Center Durham North Carolina 27710
University Hospitals of Cleveland Cleveland Ohio 44106
The Cleveland Clinic Foundation Cleveland Ohio 44195
Ohio State University Columbus Ohio 43210
Legacy Clinic Northwest Portland Oregon 97239
Allegheny General Hospital Pittsburgh Pennsylvania 15212
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Medical University of South Carolina Charleston South Carolina 29425
Vanderbilt University Medical Center Nashville Tennessee 37232
UT Southwestern Dallas Texas 75235
Baylor College of Medicine, Pulmonary & Critical Care Houston Texas 77030
The University of Texas Health Science Center at San Antonio San Antonio Texas 78229
Intermountain Medical Center Murray Utah 84143
Inova Transplant Center Fairfax Virginia 22042
University of Washington Medical Center Seattle Washington 98195
Heart Care Associates Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00325442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 1, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00325442 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →